吴迪, 陈应靖, 李媛, 闵妍. 艾地苯醌联合舍曲林对抑郁症认知损害的早期改善作用[J]. 实用临床医药杂志, 2021, 25(1): 97-99, 103. DOI: 10.7619/jcmp.20200814
引用本文: 吴迪, 陈应靖, 李媛, 闵妍. 艾地苯醌联合舍曲林对抑郁症认知损害的早期改善作用[J]. 实用临床医药杂志, 2021, 25(1): 97-99, 103. DOI: 10.7619/jcmp.20200814
WU Di, CHEN Yingjing, LI Yuan, MIN Yan. Effect of sertraline combined with idebenone in early improvement of depression-induced cognitive impairment[J]. Journal of Clinical Medicine in Practice, 2021, 25(1): 97-99, 103. DOI: 10.7619/jcmp.20200814
Citation: WU Di, CHEN Yingjing, LI Yuan, MIN Yan. Effect of sertraline combined with idebenone in early improvement of depression-induced cognitive impairment[J]. Journal of Clinical Medicine in Practice, 2021, 25(1): 97-99, 103. DOI: 10.7619/jcmp.20200814

艾地苯醌联合舍曲林对抑郁症认知损害的早期改善作用

Effect of sertraline combined with idebenone in early improvement of depression-induced cognitive impairment

  • 摘要:
      目的  观察艾地苯醌联合舍曲林对抑郁症患者认知损害的早期改善作用。
      方法  将40例抑郁症患者随机分为2组,研究组采用艾地苯醌联合舍曲林治疗,对照组单用舍曲林治疗。比较2组患者治疗前和治疗1、2个月后的汉密尔顿抑郁量表(HAMD)评分,比较2组患者治疗后的不良反应发生率。
      结果  治疗前, 2组HAMD总分、各因子评分比较,差异均无统计学意义(P > 0.05); 治疗1、2个月后, 2组HAMD总分均低于治疗前,差异有统计学意义(P < 0.05); 治疗1个月后,研究组认知障碍因子评分低于对照组,差异有统计学意义(P < 0.05); 治疗2个月后,2组HAMD总分、各因子评分比较,差异均无统计学意义(P > 0.05)。2组不良反应发生率比较,差异无统计学意义(P > 0.05)。
      结论  艾地苯醌联合舍曲林对抑郁症患者认知损害具有早期改善作用,且不良反应较少。

     

    Abstract:
      Objective  To observe effect of sertraline combined with idebenone in early improvement of depression-induced cognitive impairment.
      Methods  A total of 40 depression patients were randomly divided into two groups. The study group was treated with idebenone combined with sertraline, and the control group was treated with sertraline alone. The Hamilton Depression Scale (HAMD) scores before and at 1 month and 2 months after treatment as well as incidence of adverse reactions were compared.
      Results  Before treatment, there were no significant differences in total score of HAMD and scores of each factor between the two groups (P > 0.05). After 1 month and 2 months of treatment, the total scores of HAMD in both groups were significantly lower than those before treatment (P < 0.05). After 1 month of treatment, the cognitive impairment factor score of the study group was significantly lower than that of the control group(P < 0.05). After 2 months of treatment, there were no statistical significant differences in the total score of HAMD and the score of each factor between the two groups (P > 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05).
      Conclusion  Idebenone combined with sertraline has the function of improving the cognitive impairment of depression in early stage and reducing adverse reactions.

     

/

返回文章
返回